Not yet recruiting
Colon cancer
Not yet recruitingNeoadjuvant Pembrolizumab and Porustobart for Resectable pMMR/MSS Colon Cancer: A Phase 2 Study of Efficacy and Safety in Eligible Patients
Registered drugNo placebo
Neoadjuvant Pembrolizumab and Porustobart for Resectable pMMR/MSS Colon Cancer: A Phase 2 Study of Efficacy and Safety in Eligible Patients
Registered drugNo placebo
- Disease:Colon cancer
- Substances:Pembrolizumab
Countries:
Belgium
Belgium- Participants:18–64 years · 65+ years
- Substances:Pembrolizumab
- Sponsor:Solstice Oncology Inc.


